Back to news and events

Evogene Files Registration Statement for Proposed Initial Public Offering in the United States

Rehovot, Israel, September 24, 2013 – Evogene Ltd. (TASE: EVGN) today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission for a proposed public offering of its ordinary shares in the United States. The size of the offering has not yet been finalized. Evogene has applied to have its ordinary shares listed on the New York Stock Exchange under the ticker symbol “EVGN.”


Credit Suisse Securities and Deutsche Bank Securities are the joint book-running managers for the proposed offering, and Oppenheimer & Co. and Piper Jaffray & Co. are the co-managers.                                                                                                                                                                                                                                               A copy of the preliminary prospectus related to the offering may be obtained when available from either:

Credit Suisse Securities (USA) LLC,

Attention: Prospectus Department,

One Madison Avenue, New York, NY, 10010;

or by phone at (800) 221-1037;

or by e-mail at:


Deutsche Bank Securities,

Attention: Prospectus Group,

60 Wall Street, New York, NY 10005-2836;

or by phone at 1-800-503-4611;

or by email at:


A registration statement relating to these securities has been filed with the United States Securities and Exchange Commission (SEC) but has not yet become effective.  Copies of the registration statement can be accessed through the SEC’s website at These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.




About Evogene

Evogene is a plant genomics company, utilizing a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. Evogene offers a complete solution for crop productivity improvement through biotechnology and advanced breeding using a unique technology infrastructure that is based on deep scientific understandings of plant genomics and proprietary computational capabilities. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease), in key crops as corn, soybean, wheat and rice. In addition, Evogene has earlier stage operations in agriculture chemicals and seeds for second generation feedstock for biodiesel. Evogene’s headquarters are located in Rehovot, Israel and the Company is listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN).


This press release may contain “forward-looking statements” relating to future events. These statements may be identified by words such as “may”,  “expects”,   “intends”, “proposed”, “anticipates”,  “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene’s control, including, without limitation,   those risk factors contained in Evogene’s reports filed with the Israeli Securities Authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 


Karen Mazor, Evogene

Director, Public and Investor Relations

T: +972 54 22 88 039